araag2/HINT huggingface dataset:
Clinical trial NCT00369226 (phase 1/phase 2, status: completed)
Conditions: hematologic malignancies
ICD codes: E70.338, E70.339, P09.3, O28.0, P61.8, P61.9, T45.8X1A
Drugs: bortezomib (velcade), tacrolimus, methotrexate
SMILES: CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with hematologic malignancies including myelodysplastic syndrome (MDS), who
             are at a high risk of complications after myeloablative transplantation

          -  Patients have a donor (both related and unrelated) who are mismatched according to
             protocol criteria

          -  18 years of age or older

          -  Performance status 0-2

          -  Life expectancy of > 100 days

          -  Female subject is either post-menopausal or sterilized or willing to use an acceptable
             form of birth control

          -  Male subject agrees to use an acceptable form of birth control

        Exclusion Criteria:

          -  Evidence of HIV infection

          -  Total bilirubin > 2.0mg/dl that is due to hepatocellular dysfunction

          -  Aspartate aminotransferase (AST) > 90

          -  Known active hepatitis B or C

          -  Serum creatinine > 2.0

          -  Greater than or equal to Grade 2 peripheral neuropathy within 21 days of enrollment

          -  Prior allogeneic stem cell transplant

          -  Patients with myeloproliferative disease (e.g. myelofibrosis, essential
             thrombocythemia, polycythemia vera, chronic myeloid leukemia)

          -  Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV
             hear failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities

          -  Hypersensitivity to Velcade, boron or mannitol

          -  Pregnant or breast feeding

          -  Patient has received other investigational drugs 14 days before enrollment

          -  Serious medical or psychiatric illness

          -  Another active solid tumor malignancy at the time of study entry
Clinical trial NCT01464112 (phase 1, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: jnj-2641585 / velcade / dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) Performance status score 0-2

          -  Measurable or secretory multiple myeloma

          -  Relapse or progression of myeloma following prior systemic antineoplastic therapy

          -  Pretreatment clinical laboratory values meeting protocol-specified criteria

          -  Left ventricular ejection fraction rate within normal limits

        Exclusion Criteria:

          -  Peripheral neuropathy or neuralgia >=2, according to National Cancer Institute Common
             Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0

          -  Diagnosis of primary amyloidosis, plasma cell leukemia, or other similar conditions

          -  Diagnosis of Waldenstrom macroglobulinemia with protocol-specified immunoglobulin
             levels

          -  Prior histone-deacetylase inhibitor therapy - More than 3 prior lines of therapy

          -  Cardiac risk factors: unstable angina or myocardial infarction within the preceding 12
             months, congestive heart failure (New York Heart Association Class II-IV), known
             presence of dilated, hypertrophic, or restrictive cardiomyopathy

          -  Any other cardiac abnormality that, in the opinion of the investigator, medical
             monitor, or consultant cardiologist, may place the patient at an unacceptably
             increased risk with study drug

          -  History of any of the following: sustained ventricular tachycardia, ventricular
             fibrillation, Torsades de Pointes, atrial fibrillation, cardiac arrest, Mobitz II
             second degree heart block, or third degree heart block - QTc at Screening > 450 ms in
             males / > 470 ms in females

          -  Family history of short QT syndrome, long QT syndrome

          -  Obligate use of a cardiac pacemaker - Use of medications that may cause Torsades de
             Pointes
Clinical trial NCT01373450 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: oxyntomodulin, liraglutide 0.6 mg, liraglutide 1.2 mg, placebo for oxyntomodulin, placebo for liraglutide
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a body mass index (BMI) of ≤38.0 kg/m^2

          -  Have a clinical diagnosis of Type 2 diabetes mellitus

          -  Have a glycated hemoglobin (HbA1C) at screening ≤9.0%; fasting plasma glucose should
             not exceed 300 mg/dL (16.8 mmol/L)

          -  Judged to be in good health

        Exclusion Criteria:

          -  Have a history of any illness that, in the opinion of the study investigator, might
             confound the results of the study or poses an additional risk to the subject by their
             participation in the study

          -  Have a history of stroke, chronic seizures, major neurological disorder, clinically
             significant endocrine, cardiovascular, hematological, hepatic, renal, respiratory, or
             genitourinary abnormalities or diseases

          -  Have untreated hypertension with blood pressure of >160/95 mmHg

          -  Have a history of neoplastic disease within the past 5 years

          -  Have a history of hypersensitivity to OXM, liraglutide, insulin or Haemaccel®

          -  Unable or unwilling to comply with restrictions around concomitant medications

          -  Consume excessive amounts of alcohol, coffee, tea, cola, or other caffeinated
             beverages daily

          -  Have had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or
             participated in another investigational study within 4 weeks

          -  Have a history of significant multiple and/or severe allergies, or has had an
             anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Currently a regular user (including use of any illicit drugs or has a history of drug
             (including alcohol) abuse within approximately 3 months

          -  Are unwilling or unable to consume the standardized meals during the study and/or is
             on a carbohydrate restricted diet (i.e., a diet <100 grams per day of carbohydrate)
Clinical trial NCT01704417 (phase 1, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months

          -  Body mass index 18.0-27.0 kg/m^2 (both inclusive)

          -  Subjects performing regular physical cardiorespiratory activity

          -  Glycosylated haemoglobin (HbA1c) below or equal to 9.5 %

        Exclusion Criteria:

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening

          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent
             per day)

          -  Not able or willing to refrain from smoking and use of nicotine substitute products
             during the inpatient period

          -  Supine blood pressure at screening (after resting for at least 5 minutes) outside the
             range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic
Clinical trial NCT00598104 (phase 1/phase 2, status: withdrawn)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: qax576, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    due to the lack of enrolment and complexity of design, this study in asthma was terminated. no
    subjects have been dosed for this study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  History of asthma attacks

          -  Taking inhaled corticosteroids

          -  Non-smoking

        Exclusion Criteria:

          -  Women of child-bearing potential

          -  History of respiratory disease other than asthma

          -  History of severe allergy to food or drugs

          -  Previous use of monoclonal antibodies

          -  Very low or high body weight

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00279760 (phase 1/phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: belatacept, abatacept
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of RA < 5 years

          -  Functional class I, II, or II as defined by the American College of Rheumatology (ACR)
             criteria.

          -  Must have failed at least 1 Disease Modifying Anit-Rheumatic Drug (DMARD)

          -  Joint count of 10 or more swollen and 12 or more tender.

          -  Erythrocyte Sedimentation Rate (ESR) > - 28mm/rr or norning stiffness > - 45 minutes.

        Exclusion Criteria:

          -  Women and men who are not willing to use an accepted form of contraception.

          -  Active vasculitis

          -  Treatment with another investigational drug within 30 days

          -  History of asthma, angioedema, or anaphylaxix
Clinical trial NCT01595867 (phase 1, status: completed)
Conditions: narcotic abuse, opioid-related disorders, analgesia, chronic pain
ICD codes: Z88.5, T40.491A, T40.491D, T40.491S, T40.492A, T40.492D, T40.492S, F11.14, F11.182, F11.188, F11.19, F11.24, F11.282, F11.288, P04.0, G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3
Drugs: placebo, embeda - morphine sulfate/ naltrexone hydrochloride, morphine sulfate cr crushed.
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male or female subjects 18 to 55 years of age, inclusive.

          -  Subject is a recreational opioid user who is NOT dependent on opioids based on
             Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision
             (DSM-IV-TR) criteria and the Naloxone Challenge. A recreational opioid user is defined
             as use of opioids for non-therapeutic purposes (i.e., for psychoactive effects) on at
             least 10 occasions within the last year and at least once in the 12 weeks before the
             Screening Visit (Visit 1).

          -  Subjects must have experience with intranasal drug administration, defined as
             intranasal use on at least 3 occasions within the last year prior to the Screening
             Visit.

        Exclusion Criteria:

          -  Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine), as
             assessed by the Investigator using the DSM IV-TR criteria.

          -  Has participated in, is currently participating in, or is seeking treatment for
             substance- and or alcohol-related disorders (excluding nicotine and caffeine).

          -  Has any condition in which an opioid is contraindicated; e.g., significant respiratory
             depression, acute or severe bronchial asthma or hypercarbia, or is suspected of having
             paralytic ileus.

          -  Allergy or history of hypersensitivity to morphine sulfate, other opioids, naltrexone
             hydrochloride, naloxone, and/or lactose.

          -  History or current clinically significant neurological, cardiovascular, renal,
             hepatic, endocrine, gastrointestinal, hematologic, or metabolic disease as evaluated
             by the Investigator.

          -  History or current pulmonary disease including asthma, chronic obstructive pulmonary
             disease, exercise-induced asthma, bronchitis, and obstructive sleep apnea.
Clinical trial NCT01528111 (phase 1/phase 2, status: completed)
Conditions: primary open-angle glaucoma, ocular hypertension
ICD codes: H40.053, H40.051, H40.052, H40.059
Drugs: lx7101 (0.125%), lx7101 (0.25%), lx7101 vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Adults ≥18 years of age

          -  Documented diagnosis of POAG or OHT, in both eyes

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  History of any form of glaucoma in either eye, other than POAG

          -  Subjects who are unwilling or unable to discontinue contact lens wear prior to and
             during study

          -  History of ocular trauma in either eye <6 months prior to Screening

          -  History of ocular infection or ocular inflammation in either eye <3 months prior to
             Screening

          -  History of chronic or recurrent severe inflammatory eye disease, any severe ocular
             pathology, or clinically relevant or progressive retinal diseases in either eye

          -  Clinically relevant, severe central visual field loss, or documented significant
             progression of a visual field defect within 6 months prior to Screening in either eye

          -  Use of any ocular hypertensive medications (if applicable), in either eye, during the
             washout period and for the duration of the study

          -  Use of any glucocorticoid medications <2 weeks prior to Screening and throughout the
             duration of the study

          -  Use of any medication or substance on a chronic basis which has not been taken at a
             stable dose for at least 30 days prior to Screening

          -  Use of any nondiagnostic, topical, ophthalmic preparations, in either eye, other than
             artificial tears

          -  The presence of any concurrent condition or clinically significant laboratory findings
             at Screening that may interfere with any aspect of safety, study conduct, or
             interpretation of results

          -  Women who are pregnant or breast feeding

          -  Inability or difficulty instilling eye drops
Clinical trial NCT01244620 (phase 1, status: terminated)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: sitaxentan, tadalafil, sitaxsentan, tadalafil, sitaxsentan, sildenafil
SMILES: CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl, [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl, [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl, CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
Reason stopped: 
    safety issue: the trial was prematurely terminated on dec 9, 2010, due to safety concerns,
    specifically new emerging evidence of hepatic injury.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male subjects and women of non-child bearing potential between the ages of 21
             and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities
             identified by a detailed medical history, full physical examination, including blood
             pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg (99 lbs).

          -  An informed consent document signed and dated by the subject or a legally acceptable
             representative.

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing) or clinical findings at Screening.

          -  A positive urine drug screen.

          -  Subjects with hepatic dysfunction, defined as aspartate aminotransferase (AST) and/or
             alanine aminotransferase (ALT) >1.5 times the upper limit of the normal range at
             Screening. A retest may be done if AST and/or ALT within 1.5- to 2- times the upper
             limit of the normal range at Screening, and the average of the first and repeated test
             values should be used to decide the eligibility.
Clinical trial NCT00003567 (phase 1, status: terminated)
Conditions: brain and central nervous system tumors, lymphoma, unspecified adult solid tumor, protocol specific
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: o6-benzylguanine, carmustine, temozolomide
SMILES: N=C1NC2=C(N=CN2)C(OCC2=CC=CC=C2)=N1, ClCCNC(=O)N(CCCl)N=O, CSCC[C@H](N)C(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  One of the following histologically confirmed diseases for which no curative surgical,
             radiotherapy, or chemotherapy programs are available and standard therapy offers, at
             best, a modest clinical benefit

               -  Solid tumors

               -  Gliomas

               -  Non-Hodgkin's lymphoma

          -  Primary and metastatic CNS malignancies are eligible

          -  Evaluable or measurable disease

          -  CD34 count at least 2.0 cells/μL

          -  No bone marrow involvement

               -  Histologically negative bone marrow biopsy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 70

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  At least 12 weeks

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 8.5 g/dL

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  AST and ALT less than 2.5 times normal

          -  Prothrombin time less than 1.2 times normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular:

          -  No acute cardiac disease by EKG

        Pulmonary:

          -  No symptomatic pulmonary disease

        Other:

          -  HIV negative

          -  No other severe comorbid conditions

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 2 months after study
             completion

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  See Chemotherapy

          -  No prior hematopoietic stem cell transplantation

        Chemotherapy:

          -  No prior high-dose chemotherapy

          -  Prior adjuvant chemotherapy allowed

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy to 25% or more of bone marrow

        Surgery:

          -  Not specified

        Other:

          -  At least 4 weeks since prior myelosuppressive therapy
Clinical trial NCT00510718 (phase 1, status: completed)
Conditions: prostate cancer, hormone refractory prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: mdv3100
SMILES: CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the prostate;

          2. Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH)
             analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration);

          3. Progressive disease after medical or surgical castration,

        Exclusion Criteria:

        1. Metastases in the brain or active epidural disease. (Note: patients with treated
        epidural disease are allowed);
Clinical trial NCT01347788 (phase 1, status: completed)
Conditions: prostate adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: cabozantinib
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed prostate adenocarcinoma

          -  Bone metastases confirmed by bone scan

          -  Current androgen deprivation therapy

          -  Castration-resistant disease based on progression in bone and/or PSA progression

          -  Recovered from toxicities related to prior treatment, except alopecia, lymphopenia,
             other non-clinically significant adverse events

          -  Life expectancy of greater than 3 months

          -  Normal organ and marrow function

          -  Capable of understanding and complying with the protocol requirements

          -  Agree to use medically accepted methods of contraception

          -  Able to swallow capsules

        Exclusion Criteria:

          -  More than two prior chemotherapy regimens for metastatic prostate cancer

          -  Known untreated, symptomatic or uncontrolled brain metastases

          -  Serious or unhealed wound

          -  Treatment with anticoagulants

          -  Previously identified allergy or hypersensitivity to components of the study treatment
             formulation

          -  History of a different malignancy unless disease-free for at least 5 years, or basal
             or squamous cell carcinoma of the skin

          -  Current antiretroviral therapy

          -  Uncontrolled hypertension

          -  Uncontrolled intercurrent illness
Clinical trial NCT00990496 (phase 1, status: terminated)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: fludarabine, cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    accrual goals not met
  
Eligibility criteria:

        Inclusion Criteria:

        FOR SCREENING

          -  Patients must have a histopathologic diagnosis of GBM.

          -  Patients from 5 to 65 years of age with GBM.

        FOR TREATMENT

          -  GBM has progressed following primary therapy.

          -  Tumor is CMV pp65 or IE1 positive by immunohistochemistry (IHC).

          -  Subjects must have pulse oximetry > or = 94 % on no supplemental oxygen.

          -  Creatinine clearance must be > 50 cc/min as estimated by patient's serum creatinine,
             weight, and age.

          -  Bilirubin must be < 2.0 mg/dl and SGOT/SGPT < 2.5 X normal.

          -  ECOG performance status must be < or = 2, and for patients <16 years of age, Lansky
             performance status must be > or = 70%.

        Exclusion Criteria:

          -  Pregnant females

          -  Subjects who are moribund or who because of cardiac, pulmonary, renal, hepatic or
             neurologic dysfunction are not expected to survive one month following the T cell
             infusion